Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06594315 · ClinicalTrials.gov registry record
Assessing Brain Metabolism Using MRS With Deuterated Glucose
A clinical trial of Glioma, sponsored by University of California, San Francisco.
- Active
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT06594315: Active study of Glioma, sponsored by University of California, San Francisco.
NCT06594315 is a study of Glioma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 80 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06594315, a study of Glioma, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
Primary Outcome
The signal-to-noise ratio (SNR) in metabolite concentrations will be calculated and compared on a voxel-by-voxel basis and via summary parameters (mean, median, and max) from the regions of interest (ROIs) of the anatomic and metabolic lesions on the imaging scan. Peaks with SNR \> 5.0 are considered detectable
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Blood Sample
- PROCEDURE MR spectroscopy (MRS)
- DRUG Deuterated Glucose
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2027-07-31 |
What the registry record for NCT06594315 still lists
NCT06594315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT06594315 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06594315 about?
NCT06594315 is a clinical study titled "Assessing Brain Metabolism Using MRS With Deuterated Glucose". This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
What is the current status of trial NCT06594315?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2022-07-20. Estimated completion is 2027-07-31.
What conditions does trial NCT06594315 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT06594315?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Blood Sample (PROCEDURE), MR spectroscopy (MRS) (PROCEDURE), Deuterated Glucose (DRUG).
Who is sponsoring clinical trial NCT06594315?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06594315 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06594315's enrollment target sits among peer trials
80 25th of 87 higher than 62 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI